| Literature DB >> 25974167 |
Thomas Yates1, Melanie J Davies1, Joseph Henson1, Charlotte Edwardson1, David Webb1, Danielle H Bodicoat1, M'Balu Webb2, Philip Howard3, Jackie A Cooper3, Steve E Humphries3, Kamlesh Khunti4, Philippa Talmud3.
Abstract
BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPARγ) is an important regulator of metabolic health and a common polymorphism in the PPAR-γ2 gene (PPARG2) may modify associations between lifestyle behaviour and health.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25974167 PMCID: PMC4431874 DOI: 10.1371/journal.pone.0124062
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Participant characteristics.
| Variables | Ala12 carriers (n = 98) | Pro12 homozygotes (n = 443) | P value for difference |
|---|---|---|---|
| Age(years) | 65 [59,69] | 65 [60, 69] | 0.485 |
| Sex (female) | 33 (34) | 146 (33) | 0.892 |
| Ethnicity | |||
| White European | 89 (91) | 401 (91) | 0.927 |
| South Asian | 8 (8) | 27 (6) | |
| Other | 1 (1) | 15 (3) | |
| Social Deprivation | 14.6 [8.3, 28.1] | 12.5 [7.5, 21.6] | 0.252 |
| Beta-blocker medication | 16 (16) | 76 (17) | 0.843 |
| BMI (kg/m2) | 30.9 [28.2, 34.5] | 31.4 [28.4, 34.8] | 0.776 |
| Waist Circumference (cm) | 99.0 [93.0, 107.5] | 100.0 [93.0, 109.0] | 0.654 |
| Fasting glucose (mmol/l) | 5.2 [4.9, 5.6] | 5.2 [4.9, 5.6] | 0.971 |
| 2-h glucose (mmol/l) | 6.6 [5.1, 8.2] | 5.9 [4.8, 7.8] | 0.069 |
| Fasting insulin (mU/l) | 9.8 [6.6, 13.8] | 8.7 [5.9, 12.7] | 0.065 |
| 2-h insulin(mU/l) | 60.7 [31.7, 107.2] | 43.9 [25.2, 75.3] | 0.022 |
| HOMA-IS | 0.43 [0.29, 0.68] | 0.50 [0.33, 0.76] | 0.072 |
| Matsuda-ISI | 3.7 [2.2, 7.2] | 5.3 [3.2, 9.2] | 0.007 |
| Sedentary time (average mins/day) | 623.7 [565.5, 687.7] | 615.2 [549.7, 678.3] | 0.304 |
| Moderate to vigorous intensity physical activity (average mins/day) | 33.0 [20.2, 50.8] | 32.6 [19.3, 54.2] | 0.845 |
Data displayed as median [IQR] or number (%)
* = higher values represent greater deprivation
† = Fasting insulin data missing for 12 Ala12 carriers and 50 Pro12 homozygotes due to insufficient blood collection or cessation of bleeding
‡ = 2-h insulin data missing for 14 Ala12 carriers and 59 Pro12 homozygotes due to insufficient blood collection or cessation of bleeding
§ = Matsuda-ISI data missing for 21 Ala12 carriers and 89 Pro12 homozygotes; higher values indicate greater sensitivity
Associations of moderate-to-vigorous physical activity (MVPA) and sedentary time with markers of insulin sensitivity.
| HOMA-IS | Matsuda-ISI | |||
|---|---|---|---|---|
| β | P | β | p | |
|
| ||||
| MVPA | 1.17 (1.09, 1.26) | <0.001 | 1.28(1.17, 1.40) | <0.001 |
| Sedentary | 0.94 (0.92, 0.97) | <0.001 | 0.91 (0.89, 0.94) | <0.001 |
|
| ||||
| MVPA | 1.11 (1.01, 1.22) | 0.040 | 1.17(1.03, 1.31) | 0.012 |
| Sedentary | 0.97 (0.93, 1.00) | 0.084 | 0.95 (0.91, 0.99) | 0.017 |
|
| ||||
| MVPA | 1.04 (0.95, 1.15) | 0.267 | 1.13 (1.00, 1.26) | 0.048 |
| Sedentary | 0.98 (0.95, 1.02) | 0.351 | 0.96 (0.92, 1.00) | 0.043 |
Coefficients represent the factor by which the measure of insulin sensitivity is multiplied by (95% Confidence Interval) for a 30 minute difference in sedentary time or MVPA
Model 1 adjusted for age, sex, ethnicity, smoking status, statin medication status, beta-blocker status and accelerometer wear time
Model 2 adjusted for above variables plus MVPA (for the sedentary time model) or sedentary time (for the MVPA model)
Model 3 adjusted for the above plus BMI
Associations of moderate-to-vigorous physical activity (MVPA) and sedentary time with Matsuda-ISI after stratification byPro12Ala genotype.
| Ala12 carriers | Pro12 homozygotes | |||
|---|---|---|---|---|
| β | P | β | p | |
| MVPA | 1.69 (1.16, 2.45) | 0.007 | 1.10 (0.97, 1.24) | 0.113 |
| Sedentary time | 1.00 (0.88, 1.13) | 0.994 | 0.94 (0.90, 0.99) | 0.015 |
Coefficients represent the factor by which the measure of insulin sensitivity is multiplied by (95% Confidence Interval) for a 30 minute difference in sedentary time or MVPA
Adjusted for age, sex, ethnicity, smoking status, statin medication status, beta-blocker status, accelerometer wear time and MVPA (for the sedentary time model) or sedentary time (for the MVPA model)